Influence
August 24, 2021

Regenstrief research scientist contributes to new national stroke treatment guideline

A Regenstrief Institute research scientist has helped author new national guidelines to reduce the risk of a second stroke.

Neurologist Linda Williams, M.D., is a member of the American Heart Association writing group for the updated guideline titled “2021 Guideline for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack.”  In addition to her role at Regenstrief, Dr. Williams is affiliated with the U.S. Department of Veterans Affairs and Indiana University School of Medicine.

The new guideline encourages providers to tailor stroke prevention strategies based on the cause of the stroke.

Dr. Williams is an experienced neurologist who has conducted extensive research on stroke and TIA care. In this report, she authored the sections on homocysteine, embolic stroke of undetermined source and the use of antithrombotic medications.

As a writing group member, Dr. Williams reviewed all sections of the guidelines. This update is the first since 2014.

About Linda Williams, M.D.

In addition to her role as a research scientist at Regenstrief, Linda S. Williams, M.D., is a core investigator for the U.S. Department of Veterans Affairs Health Services Research and Development Center for Health Information and Communication, Richard L. Roudebush VA Medical Center. She also is a professor of neurology at Indiana University School of Medicine.

Related News

Rachel Patzer, PhD

Factors Affecting Treatment Selection Among Patients With Hidradenitis Suppurativa

Published in JAMA Dermatology. Here is a link to the article.   Regenstrief Institute authors:  Rachel Patzer, PhD, MPH

Thomas Imperiale

Next generation stool DNA test has best detection rate of noninvasive colorectal cancer screening tools

Study of highly sensitive noninvasive test published in New England Journal of Medicine A study of more than 21,000

Rachel Patzer, PhD, MPH and Kalli Koukounas, MPH

JAMA study finds facilities treating poor patients penalized by CMS payment model

Social risk and treatment for end-stage kidney disease A new study of more than 2,000 dialysis facilities randomized to